While clinically relevant for patient management and quality-of-life, the paper offers little actionable mechanistic or therapeutic insight for Parkinson's drug discovery.

Emphasizing GBA1-linked lysosomal dysfunction and the need for molecular stratification is directly relevant to targeting glucocerebrosidase pathways and developing biomarker-guided, disease-modifying therapies for PD.

Although lacking primary results, the paper highlights a concrete, repurposable therapeutic (sargramostim) that targets neuroinflammation and regulatory T‑cell pathways, offering translational rationale and trial-ready hypotheses for biomarker-driven interventional studies.

If validated, a sensitive serum SERS fingerprint could serve as a minimally invasive biomarker platform to track disease progression and treatment effects, improving clinical trial readouts and patient monitoring despite lacking direct mechanistic or therapeutic interventions.

Explainable, DBS-responsive gait biomarkers offer translational value for patient selection and objective monitoring of therapeutic response, but the work is clinical/phenotypic and lacks molecular or mechanistic targets for drug discovery.

Low-cost, portable EEG biomarkers could enable broader screening, remote monitoring, and patient stratification for clinical trials—useful translational tools even though they do not directly illuminate therapeutic mechanisms.

If substantiated with robust, actionable measures, neurogenesis could become a useful readout for neuroprotective or disease‑modifying interventions and help de-risk clinical trials, but current missing details limit immediate therapeutic utility.

Findings could help refine clinical biomarkers or risk stratification for cognitive decline in PD but offer limited direct mechanistic or therapeutic targets for drug discovery.

A validated multi-model demonstration of neuroprotective mechanisms or active compounds from Acacia jacquemontii could yield natural-product leads for Parkinson’s drug discovery, but the absence of accessible experimental details prevents judging its translational value.

ATXN2 CAG expansions are implicated in neurodegenerative risk including parkinsonism, so identifying intrinsic stabilizers of repeat expansion advances mechanistic understanding and potential genetic-risk modulation strategies, but the D/H isotope approach is unlikely to be directly translatable as…

While the erratum itself adds no new data, the corrected study ties retromer (VPS35) dysfunction to LRRK2-regulated lysosomal processes—mechanistically relevant to LRRK2-targeted therapies and lysosome/retromer-focused approaches in PD.

For Parkinson's therapeutic research, reliance on conference abstracts can mischaracterize trial quality and certainty of evidence, potentially skewing interpretation of intervention efficacy and priorities for follow-up studies or drug development.

High-resolution mechanistic and structural mapping of ROC-dependent activation identifies specific allosteric nodes (switch regions and R1441 coupling) that are actionable targets for rational design of modulators to normalize aberrant LRRK2 activity in Parkinson's disease.

The work maps DJ-1–dependent gene networks and highlights potentially druggable transcriptional regulators (REST, EP300) and synaptic pathways relevant to PD, offering moderate translational leads but limited by an in vitro SH-SY5Y model and minimal functional validation.

Improved quantification and sensitivity make [11C]UCB-J a more reliable synaptic-density biomarker for patient selection, longitudinal monitoring, and assessing target engagement or efficacy in PD therapeutic trials.

By delivering a large, ancestry-aware, and uniformly processed PD genomic dataset with convenient variant- and gene-level summaries, the browser materially accelerates identification and prioritization of risk and causal variants for target nomination, cohort stratification, and biomarker…

By pinpointing specific retromer interaction losses, the study highlights mechanistic targets (retromer/TBC1D5/VPS29) for strategies to restore endosomal sorting in VPS35-linked PD, though it does not yet provide direct therapeutic leads.

Provides proof-of-concept that a non-invasive peripheral vibrotactile stimulus can acutely modulate spinal and supraspinal sensorimotor circuits to reduce freezing-related gait abnormalities, supporting development of wearable symptomatic therapies and further clinical testing.

Highlights lysosomal cathepsins (especially cathepsin F) as plausible causal contributors and potential biomarker/therapeutic targets for PD, providing a genetically informed rationale for follow-up functional studies and target validation despite requiring replication.

The paper identifies a simple, implementable rehabilitation strategy that enhances motor learning and a neurophysiological marker of plasticity in PD, offering actionable guidance for clinical therapy design though it does not address disease-modifying mechanisms.

Delivers objective, event-level sensor biomarkers that can improve phase-aware FoG detection, remote monitoring, patient stratification, and outcome measurement for symptomatic/cueing interventions, though it offers little direct insight into disease-modifying biology.

Offers a noninvasive imaging biomarker (NAI) to detect early nigrostriatal vulnerability and stratify/monitor at-risk older adults for PD-related research and trials, though it lacks direct molecular therapeutic targets.

The work provides potential biomarkers and mechanistic guidance for stratifying patients and optimizing non‑invasive neuromodulation (TMS/PAS) therapies in PD, though it does not identify molecular drug targets for pharmacological discovery.

Offers a translational, ecologically valid EEG biomarker method to detect and quantify PD-related postural control dysfunction for diagnosis, stratification, and treatment monitoring, though it lacks direct mechanistic or therapeutic targets.

Demonstrates that objective, real-world wearable metrics can function as digital biomarkers to monitor motor symptom severity and support trial/outcome measurement, but provides minimal mechanistic or direct therapeutic-discovery insights.